Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 472)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
2 |
|
Bupropion |
Approved |
Phase 4 |
|
31677-93-7, 34841-39-9, 34911-55-2 |
444 |
Synonyms:
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
Amfebutamona
Amfebutamone
AMFEBUTAMONE HCL
amfebutamone|BW-323|Wellbutrin®|Zyban®
Amfebutamonum
BUPROPION
BUPROPION HCL
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion, (+-)-isomer
BW-323
Esteve brand OF bupropion hydrochloride
FORFIVO XL
glaxo Wellcome brand 1 OF bupropion hydrochloride
|
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
NSC-315851
Quomen
Wellbatrin
Wellbutrin
WELLBUTRIN 100
WELLBUTRIN 75
WELLBUTRIN SR
WELLBUTRIN XL
Zyban
Zyban (anti-smoking)
Zyban (bupropion)
Zyntabac
|
|
3 |
|
Nicotine |
Approved |
Phase 4 |
|
54-11-5 |
942 89594 |
Synonyms:
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+)-Nicotine
(+-)-Nicotine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(RS)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
a -N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
Bitartrate, nicotine
Black Leaf
Black Leaf 40
Campbell's Nico-Soap
Commit
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
Habitrol
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
|
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Niagara P.A. Dust
NICABATE
Nicocide
Nicoderm
NICODERM CQ
Nico-Dust
Nico-Fume
NICOPASS
NICOPATCH
Nicorette
NICORETTE INVISI
Nicorette Plus
Nicorette®|Nicotrol®
Nicotin
Nicotina
Nicotine
Nicotine alkaloid
Nicotine betadex
Nicotine bitartrate
Nicotine polacrilex
Nicotine tartrate
NICOTINELL CLASSIC
NICOTINELL SUPPORT
NICOTINELL TTS 10
NICOTINELL TTS 20
NICOTINELL TTS 30
NICOTROL
NICOTROL INHALER
NICOTROL NS
Nic-Sal
Nikotin
Nikotyna
NIQUITIN
NIQUITIN CLR
NIQUITIN MINIS CHERRY
NIQUITIN MINIS MINT
NIQUITIN MINIS ORANGE
NIQUITIN MINT
NIQUITIN PRE-QUIT
NIQUITIN STRIPS MINT
Ortho N-4 Dust
Ortho N-5 Dust
PROSTEP
R)-(+)-Nicotine
STOPPERS
STUBIT
Tartrate, nicotine
Tendust
|
|
4 |
|
Ropivacaine |
Approved |
Phase 4 |
|
84057-95-4 |
71273 175805 |
Synonyms:
(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(-)-1-Propyl-2',6'-pipecoloxylidide
(+-)-Ropivacaine
(S)-(-)-1-Propyl-2',6'-pipecoloxylidide
(S)-(−)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE
(S)-ROPIVACAINE
1 Propyl 2',6' pipecoloxylidide
1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-Propyl-2',6'-pipecoloxylidide
1-propyl-2',6'-pipecoloxylidide|AL-381|LEA-103|Naropin®|ropivacaine hydrochloride
AL-381
DL-Ropivacaine
LEA 103
LEA-103
L-N-N-Propylpipecolate-2,6-xylidide
L-N-N-Propylpipecolic acid-2,6-xylidide
Naropeine
|
Naropin
N-N-Propylpipecolate-2,6-xylidide
N-N-Propylpipecolic acid-2,6-xylidide
Racemic ropivacaine
rac-Ropivacaine
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacaine monohydrochloride, (S)-isomer
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
|
|
5 |
|
Papaverine |
Approved, Investigational |
Phase 4 |
|
61-25-6, 58-74-2 |
4680 |
Synonyms:
Cerespan
Chlorhydrate de papaverine
Hydrochloride, papaverine
Mesotina
NSC-136630
Papavarine chlorhydrate
Papaverin
Papaverina
|
PAPAVERINE
Papaverine chlorohydrate
Papaverine hydrochloride
Papaverine monohydrochloride
Papaverinium chloride
Pavabid
Pavatym
|
|
6 |
|
Dexmedetomidine |
Approved, Experimental, Vet_approved |
Phase 4 |
|
86347-14-0, 113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
(+-)-4-(a,2,3-Trimethylbenzyl)imidazole
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole
(+-)-4-(Α,2,3-trimethylbenzyl)imidazole
(+)-MEDETOMIDINE
(±)-4-(α,2,3-trimethylbenzyl)imidazole
(S)-MEDETOMIDINE
Dexdor
Dexdor®|Igalmi® (dexmedetomidine sublingual film)|MPV 1440|Precedex®
DEXMEDETOMIDIN
Dexmedetomidina
DEXMEDETOMIDINE
DEXMÉDÉTOMIDINE
Dexmedetomidine hydrochloride
Dexmedetomidinum
|
Domitor
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Hydrochloride, medetomidine
Levomedetomidine
Medetomidina
Medetomidina [Spanish]
Medetomidine
Medetomidine hydrochloride
Medetomidinum
Medetomidinum [Latin]
MPV 1440
MPV 785
MPV-1440
MPV-785
Precedex
|
|
7 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
ABSTRAL
Abstral®|Actiq®|Durogesic®|Effentora®|MCN-JR-4263-49|R-4263|Sublimaze®
ACTIQ
AD 923
AD-923
BREAKYL
Cephalon brand OF fentanyl buccal oravescent
Duragesic
DURAGESIC-100
DURAGESIC-12
DURAGESIC-25
DURAGESIC-37
DURAGESIC-50
DURAGESIC-75
Durogesic
DUROGESIC DTRANS
EFFENTORA
FENCINO
FENTALIS RESERVOIR
Fentanest
Fentanil
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl CII
Fentanyl citrate
FENTANYL-100
FENTANYL-12
FENTANYL-25
FENTANYL-37
FENTANYL-50
FENTANYL-62
FENTANYL-75
FENTANYL-87
Fentanylum
|
Fentanylum [INN-Latin]
Fentora
IDS-NF-001
INNOVAR
IONSYS
Janssen pharmaceutica brand OF fentanyl
LEPTANAL
MATRIFEN
MCN-JR-4263-49
MEZOLAR MATRIX
MYLAFENT
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N02AB03
Nasalfent
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
OPIODUR
ORALET
OSMACH
OSMANIL
PECFENT
Pentanyl
Phentanyl
R 4263
R-4263
Rapinyl
RECIVIT
Sentonil
Sublimaze
Subsys
TILOFYL
Transmucosal oral fentanyl citrate
VICTANYL
YEMEX
|
|
8 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
9 |
|
Droperidol |
Approved, Vet_approved |
Phase 4 |
|
548-73-2 |
3168 |
Synonyms:
1-(1-(3-(p-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-(1-(4-(p-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
Dehidrobenzperidol
Dehydrobenzperidol
DRIDOL
Droleptan
Droperidol
Dropéridol
|
Droperidolo
Droperidolum
Inapsine
Janssen brand OF droperidol
Kern brand OF droperidol
MCN-JR-4749
NSC-169874
R-4749
Taylor brand OF droperidol
|
|
10 |
|
Sunitinib |
Approved, Investigational |
Phase 4 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
11 |
|
Everolimus |
Approved |
Phase 4 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
12 |
|
Analgesics |
|
Phase 4 |
|
|
|
13 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
14 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
15 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
16 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
17 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
18 |
|
Dopamine Uptake Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
20 |
|
Antidepressive Agents |
|
Phase 4 |
|
|
|
21 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Central Nervous System Stimulants |
|
Phase 4 |
|
|
|
23 |
|
Nicotinic Agonists |
|
Phase 4 |
|
|
|
24 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
25 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
26 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
27 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
28 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
29 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
30 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
31 |
|
interferons |
|
Phase 4 |
|
|
|
32 |
|
Blood Substitutes |
|
Phase 4 |
|
|
|
33 |
|
Plasma Substitutes |
|
Phase 4 |
|
|
|
34 |
|
Hydroxyethyl Starch Derivatives |
|
Phase 4 |
|
|
|
35 |
|
Minocycline |
Approved, Investigational |
Phase 3 |
|
10118-90-8, 13614-98-7 |
54675783 5281021 |
Synonyms:
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-Dimethylamino-6-demethyl-6-deoxytetracycline
ACNAMINO
AKNEMIN
AKNEMIN 50
Alti-Minocycline
Apo-Minocycline
ARESTIN
BLEMIX 100
BLEMIX 50
CYCLOMIN
DENTOMYCIN
DYNACIN
Gen-Minocycline
KLINOMYCIN
MINO
Minociclina
Minociclina [INN-Spanish]
Minociclinum
MINOCIN
|
MINOCIN 50
MINOCIN MR
MINOCYCLIN
MINOCYCLINE
MINOCYCLINE HCL
MINOCYCLINE HYDROCHLORIDE
MINOCYCLINUM
Minocyclinum [INN-Latin]
Minocyn
MINOGAL
MINOLIRA
Minomycin
Novo-Minocycline
NSC-141993
SEBOMIN
SEBREN MR
SOLODYN
VECTRIN
XIMINO
|
|
36 |
|
Sorbitol |
Approved, Investigational |
Phase 3 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
37 |
|
Axitinib |
Approved, Investigational |
Phase 3 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
38 |
|
Diphenhydramine |
Approved, Investigational |
Phase 3 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
[2-(DIPHENYLMETHOXY)ETHYL]DIMETHYLAMINE
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
ANTITUSSIVE
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
BELDIN
BELIX
Benadryl
BENADRYL PRESERVATIVE FREE
Benadryl®|benzhydramine|dimehydrinate
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
CALADRYL
Citrate, diphenhydramine
COLTEX
DIBENIL
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
DIMEHYDRINATE
Dimethylamine benzhydryl ester
Diphamine
Diphantine
|
DIPHEN
DIPHENHYDRAMINE
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
DIPHENHYDRAMINE HCL
Diphenhydramine hydrochloride
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
DREEMON
DYTUSS
FEDRIL
GPPE COUGH EXPECT PAED
GPPE ORAL SOLN
HISTERGAN
HYDRAMINE
Hydrochloride, diphenhydramine
MEDINEX
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
NIGHTCALM
NSC-33299
NYTOL
NYTOL ONE-A-NIGHT
O-Benzhydryldimethylaminoethanol
PAXIDORM
Restamin
SILPHEN
SLEEPIA
SYNTEDRIL
TIXYLIX CATARRH
VICKS FORMULA 44
Α-(2-dimethylaminoethoxy)diphenylmethane
Β-dimethylaminoethanol diphenylmethyl ether
Β-dimethylaminoethyl benzhydryl ether
|
|
39 |
|
Promethazine |
Approved, Investigational |
Phase 3 |
|
60-87-7 |
4927 |
Synonyms:
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
Atosil
Diphergan
Diprazin
Hydrochloride, promethazine
Isopromethazine
Lilly 1516
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
NSC-30321
Phenargan
Phenergan
Phenergan®|Sominex®
Phensedyl
Pipolfen
Pipolphen
Proazaimine
Proazamine
|
Promazinamide
Promet
Prometazin
Prometazina
Prometazine
PROMETHACON
Promethazin
PROMETHAZINE
Promethazine hydrochloride
Promethazinum
PROMETHEGAN
Promethiazine
Promezathine
Prothazin
Prothazine
Pyrethia
Remsed
RP-3277
Rumergan
SOMINEX
ZIPAN-25
ZIPAN-50
|
|
40 |
|
Sargramostim |
Approved, Investigational |
Phase 3 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
41 |
|
Medroxyprogesterone acetate |
Approved, Investigational |
Phase 3 |
|
520-85-4, 71-58-9 |
6279 10631 |
Synonyms:
(6ALPHA)-17-(ACETYLOXY)-6-METHYLPREG-4-ENE-3,20-DIONE
(6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha methylprogesterone
17 alpha-Hydroxy-6 alpha-methylprogesterone
17-ACETOXY-6ALPHA-METHYLPROGESTERONE
17-ACETOXY-6Α-METHYLPROGESTERONE
17a-Hydroxy-6a-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone
17ALPHA-HYDROXY-6ALPHA-METHYLPROGESTERONE ACETATE
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17-Hydroxy-6a-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6α-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6α-methylprogesterone
17Α-hydroxy-6α-methylprogesterone
17Α-HYDROXY-6Α-METHYLPROGESTERONE ACETATE
6ALPHA-METHYL-17-ACETOXY PROGESTERONE
6-ALPHA-METHYL-17-ALPHA-ACETOXYPROGESTERONE
6alpha-Methyl-17alpha-hydroxyprogesterone
6ALPHA-METHYL-17ALPHA-HYDROXYPROGESTERONE ACETATE
6-ALPHA-METHYL-17-ALPHA-HYDROXYPROGESTERONE ACETATE
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6ALPHA-METHYL-4-PREGNENE-3,20-DION-17ALPHA-OL ACETATE
6a-Methyl-17a-hydroxyprogesterone
6a-Methyl-4-pregnen-17a-ol-3,20-dione
6Α-METHYL-17-ACETOXY PROGESTERONE
6Α-methyl-17α-hydroxyprogesterone
6Α-METHYL-17Α-HYDROXYPROGESTERONE ACETATE
6Α-methyl-4-pregnen-17α-ol-3,20-dione
6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
ADGYN MEDRO
AMEN
Aragest
Aragest 5
Asconale
CBP-1011
CLIMANOR
Clinofem
Clinovir
Colirest
CURRETAB
CYCRIN
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
DEPO-PROGEVERA
Depo-Promone
DEPO-PROVERA
DEPO-PROVERA ONCOLOGY
DEPO-SUBQ PROVERA 104
Depot-Medroxyprogesterone acetate
DMPA
FARLUTAL
FARLUTAL 100
FARLUTAL 200
FARLUTAL 250
FARLUTAL 500
Farlutal inyectable
|
Farlutin
Gestapuran
G-Farlutal
Hematrol
Hydroxymethylprogesterone
hydroxymethylprogesterone|MPA
Hysron
Indivina
LUNELLE
Lutopolar
Lutoral
MAP
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
MEDROXIPROGESTERONE ACETATE
Medroxiprogesteronum
MEDROXYACETATE PROGESTERONE
Medroxyprogesteron
Medroxyprogesteron acetate
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE 17-ACETATE
MEDROXYPROGESTERONE ACETATE
Medroxyprogesterone strakan brand
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
METHYLACETOXYPROGESTERONE
Methylhydroxyprogesterone
METIGESTRONA
MPA
MPA Gyn 5
Nadigest
Nidaxin
Novo-Medrone
NSC-21171
NSC-26386
Oragest
Perlutex
Perlutex Leo
PREMPRO
Prodasone
Progestalfa
Progevera
PROVERA
Proverone
Ralovera
Repromap
Repromix
SAYANA PRESS
Sirprogen
Sodelut G
Strakan brand OF medroxyprogesterone
TV-46046
Veramix
|
|
42 |
|
Trimethoprim |
Approved, Vet_approved |
Phase 3 |
|
738-70-5 |
5578 |
Synonyms:
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
BW-5672
BW-56-72
CO-Trimoxazole
IPRAL
LEDATRIM
MONOTRIM
NIH-204
NSC-106568
POLYTRIM
PRIMSOL
Proloprim
PROLOPRIN
|
SYRAPRIM
TCMDC-125538
TIEMPE
TMP
TRIMETHOPRIM
TRIMETHOPRIME
TRIMÉTHOPRIME
TRIMETHOPRIMUM
TRIMETOPRIMA
TRIMOGAL
TRIMOPAN
Trimpex
TRIMPEX 200
TRIPRIMIX 200
|
|
43 |
|
Sulfamethoxazole |
Approved |
Phase 3 |
|
723-46-6 |
5329 |
Synonyms:
3-(p-Aminobenzenesulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulfonamido)-5-methylisoxazole
3-(p-Aminophenylsulphonamido)-5-methylisoxazole
3-(Para-aminophenylsulphonamido)-5-methylisoxazole
3-Sulfanilamido-5-methylisoxazole
3-Sulphanilamido-5-methylisoxazole
4-Amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide
4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulphonamide
5-Methyl-3-sulfanilamidoisoxazole
5-Methyl-3-sulfanylamidoisoxazole
5-Methyl-3-sulfonylamidoisoxazole
5-Methyl-3-sulphanil-amidoisoxazole
ACETYLSULFAMETHOXAZOLE
Apo-Sulfamethoxazole
Azo Gantanol
Azo-gantanol
Bactrim
Bactrimel
Gamazole
Gantanol
GANTANOL (TN)
GANTANOL-DS
Metoxal
N'-(5-methyl-3-isoxazole)sulfanilamide
N'-(5-methyl-3-isoxazolyl)sulfanilamide
N'-(5-methyl-3-isoxazolyl)-sulfanilamide
N'-(5-methylisoxazol-3-yl)sulphanilamide
N^1-(5-methyl-3-isoxazolyl)-sulfanilamide
N1-(5-Methyl-3-isoxazolyl)sulfanilamide
N1-(5-Methyl-3-isoxazolyl)-sulfanilamide
|
N1-(5-Methyl-3-isoxazolyl)sulphanilamide
Ndimethyl1-(5-methyl-3-isoxazolyl)-sulfanilamide
NSC-147832
Radonil
RO-42130
RO-4-2130
Septran
SIM
Simsinomin
Sinomin
SMX
SMZ
STX-608
Sulfamethalazole
Sulfamethoxazol
SULFAMETHOXAZOLE
SULFAMETHOXAZOLE SODIUM
Sulfamethoxazole(usan)
Sulfamethoxizole
Sulfamethylisoxazole
Sulfametoxazol
Sulfisomezole
Sulphamethalazole
Sulphamethoxazol
Sulphamethoxazole
Sulphamethoxazole BP 98
Sulpha-methoxizole
Sulphamethylisoxazole
Sulphisomezole
SUPHAMETHOXAZOLE
Trib
UROBAK
|
|
44 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 2, Phase 3 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
45 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
46 |
|
Clonidine |
Approved |
Phase 2, Phase 3 |
|
4205-91-8, 4205-90-7 |
2803 20179 |
Synonyms:
2-((2,6-Dichlorophenyl)imino)imidazolidine
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2-[(2,6-Dichlorophenyl)imino]imidazoline
Adesipress
Boehringer ingelheim brand OF clonidine hydrochloride
Catapres
CATAPRES P.L.
CATAPRES TTS 1
CATAPRES TTS 2
CATAPRES TTS 3
Catapres®|Kapvay®
Catapresan
Catapressan
Catapres-TTS
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
Catarpres
Catarpresan
Catarpres-TTS
Chlofazoline
Chlophazolin
Chlornidinum
Clofelin
Clofenil
Clonidin
Clonidina
Clonidine
Clonidine dihydrochloride
CLONIDINE HCL
Clonidine hydrochloride
|
Clonidine monohydrobromide
Clonidine monohydrochloride
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
CLORPRES
COMBIPRES
DICHLORANILINO IMIDAZOLIN
Dihydrochloride, clonidine
Dixarit
DURACLON
Duraclont
Gemiton
Hemiton
Hydrochloride, clonidine
Ipotensium
Isoglaucon
JENLOGA
KAPVAY
KAPVAY®
Klofelin
Klofenil
Monohydrobromide, clonidine
Monohydrochloride, clonidine
ST 155BS
ST-155
ST-155BS
ST-155-BS
Tenso-Timelets
|
|
47 |
|
Thrombin |
Approved, Investigational |
Phase 3 |
|
|
|
Synonyms:
coagulation factor II
THROMBIN
Thrombin bovine
|
Thrombin, Topical (Bovine)
THROMBOSTAT
|
|
48 |
|
Dopamine |
Approved |
Phase 3 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
49 |
|
Avelumab |
Approved, Investigational |
Phase 3 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
50 |
|
Memantine |
Approved, Investigational |
Phase 3 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
Interventional clinical trials:
(show top 50)
(show all 1800)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors |
Unknown status |
NCT00777504 |
Phase 4 |
usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor |
2 |
Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method |
Completed |
NCT02988219 |
Phase 4 |
Bupivacaine-fentanyl |
3 |
Enhancing Tobacco Use Treatment for African American Light Smokers |
Completed |
NCT00666978 |
Phase 4 |
bupropion hydrochloride |
4 |
Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study |
Completed |
NCT04162834 |
Phase 4 |
Papaverine;Normal saline |
5 |
Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin |
Completed |
NCT00006864 |
Phase 4 |
|
6 |
Comparing the Lozenge to the Patch for Smoking Cessation |
Completed |
NCT00365508 |
Phase 4 |
nicotine lozenge;nicotine patch |
7 |
Safety Study of Nivolumab for Selected Advanced Malignancies in India |
Completed |
NCT03444766 |
Phase 4 |
Nivolumab |
8 |
Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer |
Completed |
NCT03514550 |
Phase 4 |
Propofol;Sevoflurane |
9 |
A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma |
Completed |
NCT01521715 |
Phase 4 |
Pazopanib |
10 |
Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment |
Completed |
NCT02056587 |
Phase 4 |
Everolimus |
11 |
Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies |
Completed |
NCT00414765 |
Phase 4 |
Aldesleukin |
12 |
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) |
Completed |
NCT02596035 |
Phase 4 |
Nivolumab |
13 |
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma |
Completed |
NCT02555748 |
Phase 4 |
Pazopanib;Sunitinib |
14 |
A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) |
Completed |
NCT00706706 |
Phase 4 |
Sunitinib Malate (SU011248) |
15 |
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy |
Completed |
NCT01266837 |
Phase 4 |
Everolimus |
16 |
An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib |
Completed |
NCT01514448 |
Phase 4 |
Everolimus (RAD001) |
17 |
An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). |
Completed |
NCT01206764 |
Phase 4 |
RAD001 |
18 |
Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) |
Completed |
NCT02982954 |
Phase 4 |
Nivolumab;Ipilimumab |
19 |
Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours |
Completed |
NCT02016391 |
Phase 4 |
Dexmedetomidine |
20 |
A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy |
Recruiting |
NCT03824808 |
Phase 4 |
Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection |
21 |
A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India |
Recruiting |
NCT04513522 |
Phase 4 |
|
22 |
Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial |
Recruiting |
NCT05068180 |
Phase 4 |
low-dose neuroleptanalgesia;Placebo |
23 |
Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery |
Terminated |
NCT01486550 |
Phase 4 |
Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml |
24 |
A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma |
Terminated |
NCT02570789 |
Phase 4 |
patients with sunitinib or pazopanib |
25 |
A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy |
Terminated |
NCT00930345 |
Phase 4 |
Sunitinib (SUTENT) |
26 |
A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma |
Terminated |
NCT00352859 |
Phase 4 |
Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only) |
27 |
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor |
Terminated |
NCT02338570 |
Phase 4 |
Everolimus |
28 |
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy |
Terminated |
NCT01413607 |
Phase 4 |
|
29 |
Nephroblastoma (Wilms Tumour) Clinical Trial And Study |
Unknown status |
NCT00047138 |
Phase 3 |
carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate |
30 |
Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma |
Unknown status |
NCT01099423 |
Phase 3 |
|
31 |
Nephroblastoma Clinical Trial and Study |
Unknown status |
NCT00003804 |
Phase 3 |
vincristine sulfate |
32 |
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail |
Unknown status |
NCT02928692 |
Phase 3 |
Minocycline;Placebo |
33 |
Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) |
Unknown status |
NCT00869011 |
Phase 3 |
|
34 |
Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma |
Unknown status |
NCT01481870 |
Phase 3 |
Sorafenib-sunitinib;Sunitinib-sorafenib |
35 |
Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO] |
Completed |
NCT00416871 |
Phase 3 |
|
36 |
Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO] |
Completed |
NCT00416429 |
Phase 3 |
medroxyprogesterone |
37 |
SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse |
Completed |
NCT00492258 |
Phase 3 |
sorafenib tosylate |
38 |
Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer |
Completed |
NCT00369564 |
Phase 3 |
glutamic acid |
39 |
A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma |
Completed |
NCT00072046 |
Phase 3 |
|
40 |
Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma |
Completed |
NCT00053807 |
Phase 3 |
fluorouracil |
41 |
RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA |
Completed |
NCT00002641 |
Phase 3 |
doxorubicin hydrochloride;ifosfamide;isolated perfusion |
42 |
National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study |
Completed |
NCT00002610 |
Phase 3 |
carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate |
43 |
Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma |
Completed |
NCT00005966 |
Phase 3 |
thalidomide |
44 |
A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma |
Completed |
NCT00002473 |
Phase 3 |
|
45 |
A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma |
Completed |
NCT00053820 |
Phase 3 |
fluorouracil |
46 |
AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy |
Completed |
NCT00005995 |
Phase 3 |
shark cartilage extract AE-941 |
47 |
A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) |
Completed |
NCT00606632 |
Phase 3 |
124-Iodine-cG250 (124I-cG250) |
48 |
Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma |
Completed |
NCT00018941 |
Phase 3 |
|
49 |
NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY |
Completed |
NCT00002611 |
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate |
50 |
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER) |
Completed |
NCT00087022 |
Phase 3 |
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Lomustine
Medroxyprogesterone
|
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide
Vinblastine
Vinblastine Sulfate
|
Cochrane evidence based reviews: kidney neoplasms
|